STAT3 Interactors as Potential Therapeutic Targets for Cancer Treatment
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Signal transducers and activators of transcription (STATs) mediate essential signaling pathways in different biological processes, including immune responses, hematopoiesis, and neurogenesis. Among the STAT members, STAT3 plays crucial roles in cell proliferation, survival, and differentiation. While STAT3 activation is transient in physiological conditions, STAT3 becomes persistently activated in a high percentage of solid and hematopoietic malignancies (e.g., melanoma, multiple myeloma, breast, prostate, ovarian, and colon cancers), thus contributing to malignant transformation and progression. This makes STAT3 an attractive therapeutic target for cancers. Initial strategies aimed at inhibiting STAT3 functions have focused on blocking the action of its activating kinases or sequestering its DNA binding ability. More recently, the diffusion of proteomic-based techniques, which have allowed for the identification and characterization of novel STAT3-interacting proteins able to modulate STAT3 activity via its subcellular localization, interact with upstream kinases, and recruit transcriptional machinery, has raised the possibility to target such cofactors to specifically restrain STAT3 oncogenic functions. In this article, we summarize the available data about the function of STAT3 interactors in malignant cells and discuss their role as potential therapeutic targets for cancer treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Super-enhancers in the control of cell identity and disease
Hnisz, D., Abraham, B. J., Lee, T. I., Lau, A., Saint-André, V., Sigova, A. A., Hoke, H. A., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.09.053 · Cited by 3,662 · cited 1×
“Notably, STAT3 was recently reported to be one of the key transcription factors involved in the formation of super-enhancers [35,36] and this further pinpoints the role of STAT3 interactome as an exceptionally interesting drug target.”
BackgroundSelective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
Lovén, J., Hoke, H. A., Lin, C. Y., Lau, A., Orlando, D. A., Vakoc, C. R., Bradner, J. E., Lee, T. I., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.03.036 · Cited by 2,961 · cited 1×
“Thus, disrupting the structure of such super-enhancers or inhibiting the cofactors involved in the formation of super-enhancers represents a new and promising approach for cancer therapy [33,34].”
BackgroundWen, Z., Zhong, Z., & Darnell, J. E. (1995) · Cell · doi:10.1016/0092-8674(95)90311-9 · Cited by 1,974
The JAK/STAT signaling pathway
Rawlings, J. S., Rosler, K. M., & Harrison, D. A. (2004) · Journal of Cell Science · doi:10.1242/jcs.00963 · Cited by 1,858
Bowman, T., Garcia, R., Turkson, J., & Jove, R. (2000) · Oncogene · doi:10.1038/sj.onc.1203527 · Cited by 1,743 · cited 1×
“While physiological STAT3 activation is transient, rapidly returning to the basal state, STAT3 becomes inappropriately and persistently activated in a wide variety of hematopoietic and solid malignancies, including melanoma, multiple myeloma, breast, prostate, ovarian, and colon cancer [4], due to upregulation of upst…”
BackgroundHistone Deacetylase Inhibitors as Anticancer Drugs
Eckschlager, T., Plch, J., Stiborova, M., & Hrabeta, J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071414 · Cited by 1,206 · cited 1×
“Currently, panobinostat is an approved drug for the treatment of lymphoma and multiple myeloma and a number of HDAC inhibitors are in clinical trials for the treatment of various malignancies [106].”
BackgroundThe role of STATs in transcriptional control and their impact on cellular function
Bromberg, J., & Darnell, J. E. (2000) · Oncogene · doi:10.1038/sj.onc.1203476 · Cited by 1,201 · cited 1×
“Phosphorylated STAT3 can homodimerize, as well as form dimers with STAT1, and then move into the nucleus to exert its functions [9].”
BackgroundDangerous liaisons: STAT3 and NF-κB collaboration and crosstalk in cancer
Grivennikov, S. I., & Karin, M. (2010) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2009.11.005 · Cited by 1,160
Specific Inhibition of Stat3 Signal Transduction by PIAS3
Chung, C. D., Liao, J., Liu, B., Rao, X., Jay, P., Berta, P., & Shuai, K. (1997) · Science · doi:10.1126/science.278.5344.1803 · Cited by 980 · cited 3×
“The first evidence of a specific STAT3 repressor comes from the work of Chung and colleagues, who identified PIAS3 in 1997 [61].”
BackgroundInfluentialStat3 Dimerization Regulated by Reversible Acetylation of a Single Lysine Residue
Yuan, Z.-L., Guan, Y.-J., Chatterjee, D., & Chin, Y. E. (2005) · Science · doi:10.1126/science.1105166 · Cited by 790 · cited 9×
“Yuan and coworkers demonstrated that STAT3 interacted with the Histone acetyltransferase (HAT)p300/CREB-binding protein (CBP) complex in Hela and MCF-7 cells and it was acetylated on a single lysine residue, Lys 685, in response to cytokine treatment [21].”
BackgroundInfluential
Cited by
Carlini, V., Noonan, D. M., Abdalalem, E., Goletti, D., Sansone, C., Calabrone, L., & Albini, A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1161067 · Cited by 543
The Untapped Potential of Ascites in Ovarian Cancer Research and Treatment
Ford, C. E., Werner, B., Hacker, N. F., & Warton, K. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0875-x · Cited by 261
Tumor microenvironment in ovarian cancer: function and therapeutic strategy
Yang, Y., Yang, Y., Yang, J., Zhao, X., & Wei, X. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00758 · Cited by 218
“STAT3, a member of the STATs (Signal Transducers and Activators of Transcription) family, is generally inactivated and located in the cytoplasm (Laudisi et al., 2018).”
BackgroundNucleus, mitochondrion, or reticulum? STAT3 à La Carte
Avalle, L., & Poli, V. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19092820 · Cited by 74
Signal transducer and activator of transcription 3 signaling in tumor immune evasion
Zhang, L., Kuca, K., You, L., Zhao, Y., Musilek, K., Nepovimova, E., Wu, Q., Wu, W., & Adam, V. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107969 · Cited by 67
Metadata
- Authors
- Laudisi, F., Cherubini, F., Monteleone, G., & Stolfi, C.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2018-06-16
- Volume
- 19
- Issue
- 6
- Pages
- 1787
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2808687176
- Cited by
- 127
- References
- 26
- FWCI
- 6.32
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: STAT3 Interactors as Potential Therapeutic Targets for Cancer Treatment. https://app.cochat.ai/papers/10.3390/ijms19061787
- The paper
- Laudisi, F., Cherubini, F., Monteleone, G., & Stolfi, C. (2018). STAT3 Interactors as Potential Therapeutic Targets for Cancer Treatment. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms19061787
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.